Our clinical trials
As researchers who are convinced that it is science that will change medicine and the health of people who are ill, our aim is to transform cutting-edge research into revolutionary diagnostic tools. What we explore today has the potential to improve people’s lives tomorrow. Clinical trials are an essential step in this process. They allow us to assess the efficacy, quality and safety of our innovative products in vivo.
Our trials are based on a rigorous methodology and are conducted under the strict supervision of the best scientific experts in the field, guaranteeing the integrity and accuracy of our research. We also guarantee the development and validation of our saliva tests.
With each clinical trial we carry out, we come closer to our objective: to provide innovative diagnostic tools capable of changing the lives of patients and transforming the way healthcare systems operate to ensure fairer, more appropriate and more efficient treatment.
The ultimate aim of our trials is to improve patients’ quality of life. We work with the same scientific rigour to ensure that the use of our tests is comfortable and accessible to everyone in all territories. Our demand for scientific rigour is directly linked to Ziwig’s commitment to the well-being of the people we serve.
Towards a multipathology diagnostic test in gynaecology
GYNARN is a pioneering study using salivary RNA to revolutionise the diagnosis of gynaecological pathologies. Building on the success of Ziwig Endotest®, GYNARN aims to develop a simple and accurate salivary test to diagnose various gynaecological pathologies and predict response to surgical treatment. This international initiative, spanning 34 months and involving 2200 patients in 50 centres across 10 countries, marks a major step forward in our quest for effective personalised medicine for women’s health.
Towards an early diagnostic test for ovarian cancer and ovarian adnexal masses
OVARN is an innovative study designed to clarify the diagnosis of ovarian adnexal masses using salivary RNA analysis. This work is part of our mission to improve the diagnosis and medical and surgical care of patients through accurate and early identification of ovarian cancer, benign cysts and borderline tumours. Involving 600 patients across France, Belgium, Switzerland and Tunisia, this multicentre study aims to develop a diagnostic salivary signature and predict response to treatment, marking a significant advance towards targeted treatments and personalised medicine.
Towards an early diagnostic test for Amyotrophic Lateral Sclerosis (ALS): A new diagnostic era in neurology
Ziwig is committed to medical innovation in neurology with the discovery of a diagnostic signature for amyotrophic lateral sclerosis (ALS) using salivary RNA analysis. Working with reference centres in France, our bi-national study is bringing together 600 participants to shape the future of early diagnosis of ALS. By exploiting cutting-edge sequencing technologies and artificial intelligence, we aim to identify reliable biological markers, offering hope of personalised treatments and more timely interventions.
Stay connected
Sign up to be notified of the latest news and publications.
